JP7527984B2 - 重度の便秘を治療するための組成物及び方法 - Google Patents

重度の便秘を治療するための組成物及び方法 Download PDF

Info

Publication number
JP7527984B2
JP7527984B2 JP2020573085A JP2020573085A JP7527984B2 JP 7527984 B2 JP7527984 B2 JP 7527984B2 JP 2020573085 A JP2020573085 A JP 2020573085A JP 2020573085 A JP2020573085 A JP 2020573085A JP 7527984 B2 JP7527984 B2 JP 7527984B2
Authority
JP
Japan
Prior art keywords
constipation
dgat1
pharmaceutical composition
opioid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518431A (ja
JP2021518431A5 (cg-RX-API-DMAC7.html
Inventor
ケー. ハブバード,ブライアン
エイチ. セラーノ-ウー,マイケル
Original Assignee
アンジ ファーマシューティカルズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンジ ファーマシューティカルズ インコーポレーテッド filed Critical アンジ ファーマシューティカルズ インコーポレーテッド
Publication of JP2021518431A publication Critical patent/JP2021518431A/ja
Publication of JP2021518431A5 publication Critical patent/JP2021518431A5/ja
Application granted granted Critical
Publication of JP7527984B2 publication Critical patent/JP7527984B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020573085A 2018-03-16 2019-03-15 重度の便秘を治療するための組成物及び方法 Active JP7527984B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
US62/644,033 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (3)

Publication Number Publication Date
JP2021518431A JP2021518431A (ja) 2021-08-02
JP2021518431A5 JP2021518431A5 (cg-RX-API-DMAC7.html) 2022-02-21
JP7527984B2 true JP7527984B2 (ja) 2024-08-05

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573085A Active JP7527984B2 (ja) 2018-03-16 2019-03-15 重度の便秘を治療するための組成物及び方法

Country Status (24)

Country Link
US (4) US11224590B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765012B1 (cg-RX-API-DMAC7.html)
JP (1) JP7527984B2 (cg-RX-API-DMAC7.html)
KR (1) KR102747096B1 (cg-RX-API-DMAC7.html)
CN (1) CN111936137B (cg-RX-API-DMAC7.html)
AU (1) AU2019234956B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018790A2 (cg-RX-API-DMAC7.html)
DK (1) DK3765012T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092190A1 (cg-RX-API-DMAC7.html)
ES (1) ES3069001T3 (cg-RX-API-DMAC7.html)
FI (1) FI3765012T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260544T1 (cg-RX-API-DMAC7.html)
IL (1) IL277332B2 (cg-RX-API-DMAC7.html)
LT (1) LT3765012T (cg-RX-API-DMAC7.html)
MX (1) MX2020009604A (cg-RX-API-DMAC7.html)
MY (1) MY205335A (cg-RX-API-DMAC7.html)
PE (1) PE20210158A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551468A1 (cg-RX-API-DMAC7.html)
PL (1) PL3765012T3 (cg-RX-API-DMAC7.html)
PT (1) PT3765012T (cg-RX-API-DMAC7.html)
SG (1) SG11202008971VA (cg-RX-API-DMAC7.html)
SI (1) SI3765012T1 (cg-RX-API-DMAC7.html)
TW (1) TWI704917B (cg-RX-API-DMAC7.html)
WO (1) WO2019178492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave
KR102989262B1 (ko) 2020-10-21 2026-07-08 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
CA2330363C (en) 1998-06-24 2009-10-20 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Dgat阻害剤
EP1562956A4 (en) 2002-11-22 2007-10-10 Japan Tobacco Inc HETEROCYCLES CONTAINING FUSED BICYCLIC NITROGEN
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
CA2572874A1 (en) 2004-07-02 2006-01-12 Sankyo Company Limited Urea derivative
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
AU2005295453A1 (en) 2004-10-15 2006-04-27 Bayer Healthcare Llc Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
MX2007013049A (es) 2005-04-19 2008-01-11 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad.
WO2007002740A2 (en) 2005-06-28 2007-01-04 E. I. Du Pont De Nemours And Company Buffer compositions
PT2402319T (pt) * 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
SG183529A1 (en) * 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors
JP5841994B2 (ja) * 2010-04-08 2016-01-13 メディシノヴァ, インコーポレイテッド. 過敏性腸症候群の処置方法及びその治療用組成物
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013130370A2 (en) * 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
BR112015004165A2 (pt) * 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
CA2932873A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry,2017年,60(11),pp.4657-4664

Also Published As

Publication number Publication date
IL277332A (en) 2020-10-29
US20240293376A1 (en) 2024-09-05
WO2019178492A1 (en) 2019-09-19
US11819495B2 (en) 2023-11-21
SI3765012T1 (sl) 2026-06-30
US20190282549A1 (en) 2019-09-19
LT3765012T (lt) 2026-05-25
TW201944995A (zh) 2019-12-01
BR112020018790A2 (pt) 2020-10-13
IL277332B2 (en) 2025-01-01
FI3765012T3 (fi) 2026-04-17
CA3093970A1 (en) 2019-09-19
PT3765012T (pt) 2026-04-27
EP3765012B1 (en) 2026-03-04
ES3069001T3 (en) 2026-06-03
CN111936137B (zh) 2023-09-08
MY205335A (en) 2024-10-16
PH12020551468A1 (en) 2021-09-01
US20220193044A1 (en) 2022-06-23
EP3765012A4 (en) 2021-12-15
US20260000651A1 (en) 2026-01-01
MX2020009604A (es) 2023-01-25
SG11202008971VA (en) 2020-10-29
TWI704917B (zh) 2020-09-21
AU2019234956A1 (en) 2020-10-01
US11224590B2 (en) 2022-01-18
PL3765012T3 (pl) 2026-06-01
US12343334B2 (en) 2025-07-01
PE20210158A1 (es) 2021-01-26
DK3765012T3 (da) 2026-04-27
AU2019234956B2 (en) 2025-01-30
EA202092190A1 (ru) 2020-11-19
KR20200136428A (ko) 2020-12-07
JP2021518431A (ja) 2021-08-02
IL277332B1 (en) 2024-09-01
HRP20260544T1 (hr) 2026-07-17
KR102747096B1 (ko) 2024-12-26
EP3765012A1 (en) 2021-01-20
CN111936137A (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
US20260000651A1 (en) Compositions and methods for treating severe constipation
EP2582683B1 (en) Treatment of gout and hyperuricemia
JP2012500800A (ja) 神経因性疼痛の治療法
CN108882744B (zh) 含有益智提取物的组合物以及益智提取物的用途
TW202011965A (zh) 嗜中性球彈性蛋白酶抑制劑在肝病中之用途
JP2010527985A (ja) 急性躁病を治療するための医薬組成物および方法
WO2008031014A1 (en) Method for reducing or alleviating inflammation in the digestive tract
RU2307651C2 (ru) Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря
CA3093970C (en) Compositions and methods for treating severe constipation
CN117695277B (zh) 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途
KR20250168617A (ko) 염증성 장 질환의 치료를 위한 약학적 조성물
CN110831590A (zh) 含有培马贝特的医药
JP2025528218A (ja) ピロリ菌(H.pylori)感染症を予防または処置する方法
US20100305074A1 (en) Niacin-based pharmaceutical compositions
Kavadi Role of Sotagliflozin in Managing Heart Failure in Diabetes
WO2016173487A1 (en) Method for improving kidney and/or heart function in patients with kidney disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240724

R150 Certificate of patent or registration of utility model

Ref document number: 7527984

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150